LATEST
Silgan / Trivium: minority stakenewBF International Best Fields Best Food / DiagramnewOpenWorld agreed to acquire Blocksight HoldingsnewMerck KGaA agreed to acquire Silence TherapeuticsLarry A. Powalisz / Adia LabsTTM Technologies / Ophir® Optics businessTradeweb Markets agreed to acquire Trumid HoldingsCentrus Energy / Westerman HoldingsTCGX Acquisition / TriGemX BioArlington Capital Partners / Gooch & HousegoJanus Henderson Investors agreed to acquire four mutual funds managed by Nicholas CompanyEQT agreed to acquire Cleanaway
Open App
Agreement signedAgreed 21 Jun 2024

ANI Pharmaceuticals, Inc. /
Alimera

ANI Pharmaceuticals to buy Alimera in merger agreement

Buy side: ANI Pharmaceuticals, Inc.
Buy sideANI Pharmaceuticals, Inc.
Target: Alimera
TargetAlimera
Source · 21 Jun 2024Source-verified
See the source
Buy side: ANI Pharmaceuticals, Inc.
Buy sideANI Pharmaceuticals, Inc.
Target: Alimera
TargetAlimera
01 / BuyerANI Pharmaceuticals, Inc.
02 / TargetAlimera
Source-verified
01

What happened

ANI Pharmaceuticals, Inc. agreed to buy Alimera for $5.50 per share in cash at closing, plus a contingent value right tied to revenue targets in 2026 and 2027.

Alimera is a global pharmaceutical company focused on retinal health and maintaining better vision longer.

02

The source

Everything on this page comes from the source below.

01
Source · Original source

ANI Pharmaceuticals to buy Alimera in merger agreement

This document is the source for the companies, stage, figure and people on this page.

Source-verified
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

    Source-verified

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request an inviteAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.